# DSIP Peptide

> DSIP is a delta sleep-inducing nonapeptide that acts on sleep architecture, stress response, pain signaling, and neuroendocrine regulation.

Canonical: https://pepflow.app/peptides/dsip/

The Sleep Signal

DSIP stands for delta sleep-inducing peptide, a nine-amino-acid neuropeptide named from older sleep-physiology observations.

Sleep quality

Tier D

Evidence Preliminary

Safety Limited Data

FDA status Not Approved

Last reviewed October 25, 2026 29 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is DSIP?

DSIP stands for delta sleep-inducing peptide, a nine-amino-acid neuropeptide named from older sleep-physiology observations.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>)

The name is stronger than the practical evidence. DSIP is discussed for sleep, stress, pain, and withdrawal contexts, but the literature is older, mixed, and not a modern approved insomnia-drug program.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>)

DSIP is not a guaranteed sleep switch. It is better framed as a neuropeptide with sleep-related history and limited current clinical confidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) For more context, read the [DSIP side-effect evidence discussion](<https://pepflow.app/blog/dsip-side-effects/>).

## What DSIP is investigated for

DSIP evidence is grouped by practical use case and injectable and transdermal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Sleep quality and sleep architecture Injectable 43% Preliminary

Sleep has the main DSIP evidence base, but that evidence is old and not definitive.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

#### Human evidence

Older double-blind insomnia studies evaluated DSIP effects on chronic insomnia and sleep-wake behavior.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

#### Animal / mechanistic evidence

Review literature frames DSIP as a sleep-onset and sleep-architecture research tool with unresolved mechanism.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

### ### Pain modulation Injectable 38% Preliminary

Pain modulation is a small clinical signal that should be separate from sleep claims.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16539679/>)

#### Human evidence

A clinical pilot study evaluated DSIP in patients with chronic pronounced pain episodes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16539679/>)

#### Animal / mechanistic evidence

Later review literature treats pain modulation as part of the unresolved DSIP pharmacology picture.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16539679/>)

### ### Stress response modulation Injectable 30% Limited

Stress-response claims remain mechanistic and unresolved.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/3550726/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/6145137/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/3286557/>)

#### Human evidence

Human stress-response outcomes are not established in the cited DSIP literature.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/3550726/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/6145137/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/3286557/>)

#### Animal / mechanistic evidence

Older DSIP reviews discuss stress and neuroendocrine hypotheses without settling the mechanism.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/3550726/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/6145137/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/3286557/>)

### ### Stroke neurorecovery Injectable 28% Limited

Stroke neurorecovery is animal-only and separate from sleep evidence.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/34500605/>)

#### Human evidence

Human stroke-recovery outcome evidence for DSIP is not established in the cited literature.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/34500605/>)

#### Animal / mechanistic evidence

A rat focal-stroke model reported motor-function recovery after DSIP exposure.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/34500605/>)

## Evidence snapshot

### Overall confidence

Preliminary

43%

DSIP has older sleep-focused human literature plus mechanistic interest, but practical usefulness remains uncertain. Modern insomnia-level evidence is weak.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

43%

### Human evidence

Preliminary

Older human sleep literature exists but does not establish a modern insomnia treatment.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

33%

### Animal / preclinical

Limited

Mechanistic and early clinical observations support sleep-related interest, with weaker support for stress and pain outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

43%

### Mechanism support

Preliminary

DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. The proposed effect is state modulation rather than a sedative-hypnotic drug profile.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Forms & administration

DSIP has injectable research presentations and experimental transdermal preparations. Assisted skin delivery remains laboratory research, without an established human product or schedule. Preparation and delivered amount depend on the formulation.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/9876605/>)

Injectable Transdermal

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Injectable protocols use 100-300 mcg per dose. Intranasal protocols use 300 mcg per dose.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/11763019/>)

### Frequency

Injectable and intranasal protocols are usually taken once nightly.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/11763019/>)

### Timing Considerations

Take 30-60 minutes before bed.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/11763019/>)

### Cycle Length

Injectable cycles run 2-6 weeks. Intranasal courses run 5-10 days.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/11763019/>)

[Full DSIP dosage guide](<https://pepflow.app/peptides/dsip/dosage/>)

## What to expect

### First few nights

Injectable DSIP sleep-oriented use may change sleep onset, nighttime awakenings, dream intensity, or morning restfulness.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>)

### Weeks 2-4

Injectable sleep blocks may show as steadier sleep continuity, recovery feel, and next-day alertness.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>)

### After stopping

Sleep patterns may drift back toward baseline after injectable DSIP exposure ends if the benefit depends on continued use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>)

## Safety profile

DSIP safety is a sleep-neuropeptide question: next-day sedation, dream changes, headache, sedative combinations, and limited modern human data are the main issues.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

### Common side effects

- Morning grogginess [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- Vivid dreams [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- Headache [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

### Cautions

- Sedatives / alcohol[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- Mood / sleep disorder[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- Product quality[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

### What we don't know

Modern dose-ranging, interaction data, long-term sleep effects, and special-population safety remain limited.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Who DSIP is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for DSIP.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- **Untreated sleep apnea**

  Untreated sleep apnea warrants medical review or avoidance for DSIP.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- **Use with sedatives without clinician review**

  Use with sedatives without clinician review warrants medical review or avoidance for DSIP.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Sleep meds / sedatives / alcohol**

  Benzodiazepines, Z-drugs, antihistamine sleep aids, alcohol, or sedating supplements can compound next-day impairment; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- **Opioids / gabapentinoids**

  Opioids, gabapentin, or pregabalin can raise the consequence of added sleepiness or poor coordination; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- **Stimulants / caffeine**

  Stimulants or high caffeine can counter sleep effects and make sleep-response tracking unreliable; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, DSIP is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · DSIP is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Flagged · FDA safety-risk materials flag emideltide/DSIP for immunogenicity, peptide impurities, API-characterization complexity, and insufficient proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Approved

DSIP is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Flagged

FDA safety-risk materials flag emideltide/DSIP for immunogenicity, peptide impurities, API-characterization complexity, and insufficient proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[22\]](<https://www.ema.europa.eu/en/medicines>) [\[23\]](<https://products.mhra.gov.uk/>) [\[24\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[25\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat DSIP injectable route as athlete-cleared without sport-specific review.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. In practical terms, the proposed mechanism is state regulation across sleep and stress systems rather than the direct receptor action of a sedative-hypnotic drug.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

Injectable use keeps the exposure question separate from old sleep-lab observations. Because the receptor target remains diffuse and modern dose-ranging evidence is thin, the mechanism can explain research interest but cannot carry strong insomnia or recovery claims by itself. Modern trials would need to define both exposure and measurable sleep endpoints.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Research gaps & open questions

What the current literature has not yet settled about DSIP:

01

Modern randomized trials need to show whether DSIP helps people fall asleep, stay asleep, or feel better the next day compared with placebo.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

02

Researchers have not clearly established which receptor DSIP acts on or how the body absorbs, distributes, and clears it.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

03

Studies have not tested how DSIP interacts with sleep medicines, alcohol, antidepressants, antipsychotics, or other psychiatric drugs.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Common questions

### Is DSIP FDA-approved for sleep?

No. DSIP is not FDA-approved in the U.S. for sleep, and FDA lists emideltide/DSIP with compounding safety concerns.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

### Does DSIP force sleep?

No. DSIP is not a sedative-hypnotic drug; the sleep evidence is older, mixed, and not a modern insomnia protocol.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>)

### Can DSIP be combined with sleep medications?

No established safety standard exists. Sedatives, alcohol, and other sleep medications need clinician review because combination safety is not well defined.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>)

## Myths & misconceptions

### Myth

The name proves it induces sleep.

### Reality

The name reflects early research history, not a guaranteed clinical effect.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

### Myth

A neuropeptide is safer than sleep medication.

### Reality

Limited safety data and interactions still matter.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## History & discovery

DSIP was named from early work linking a peptide fraction with delta-wave sleep, then tested in small sleep and pain studies. Its history is old, intriguing, and still unresolved.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

Clinical studies tested DSIP in chronic insomnia, 24-hour sleep-wake behavior, and pronounced pain episodes. Those studies created human interest but did not mature into an approved insomnia drug.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

Later reviews repeatedly treated DSIP as a mechanistic puzzle rather than a settled therapy. That history explains why modern claims need caution around receptor target, dose, and endpoints.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/1299794/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/3622582/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/6548970/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)

## Published research 29 citations

- [\[1\] **Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.** Neuropsychobiology, 1992. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/1299794/>)
- [\[2\] **Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.** Eur Neurol, 1987. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/3622582/>)
- [\[3\] **Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.** Eur Neurol, 1984. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/6548970/>)
- [\[4\] **Delta sleep-inducing peptide.** Eur J Anaesthesiol, 2001 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/11437870/>)
- [\[5\] **Delta sleep-inducing peptide (DSIP): a still unresolved riddle.** J Neurochem, 2006 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/16539679/>)
- [\[6\] **Delta-sleep-inducing peptide (DSIP): an update.** Peptides, 1986 Nov-Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/3550726/>)
- [\[7\] **Delta-sleep-inducing peptide (DSIP): a review.** Neurosci Biobehav Rev, 1984 Spring. review.](<https://pubmed.ncbi.nlm.nih.gov/6145137/>)
- [\[8\] **DSIP--a tool for investigating the sleep onset mechanism: a review.** Int J Neurosci, 1988 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/3286557/>)
- [\[9\] **The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.** Brain Res, 1987 Jun 30. review.](<https://pubmed.ncbi.nlm.nih.gov/3620931/>)
- [\[10\] **Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.** Molecules, 2021 Aug 26. animal.](<https://pubmed.ncbi.nlm.nih.gov/34500605/>)
- [\[11\] **Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.** J Neurol, 1987 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/2448424/>)
- [\[12\] **Production and immunohistochemical application of monoclonal antibodies against delta sleep-inducing peptide.** J Chem Neuroanat, 1992 Nov-Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/1476667/>)
- [\[13\] **Drugs@FDA/openFDA query for DSIP** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22DSIP%22&limit=1>)
- [\[14\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[15\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[16\] **Effects of pH, electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide.** Drug development and industrial pharmacy, 1998 May. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/9876605/>)
- [\[17\] **Intranasal administration of delta sleep-inducing peptide increases P300.** J Clin Psychopharmacol, 2001 Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/11763019/>)
- [\[18\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[19\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[20\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[21\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[22\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[23\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[24\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[25\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[26\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[27\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[28\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[29\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Neuroactive peptide

**Tier**

D

**Evidence**

43% Preliminary

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[29 citations](<https://pepflow.app/peptides/dsip/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Sleep quality and sleep architecture
- Pain modulation
- Stress response modulation
- Stroke neurorecovery

### Common side effects

- Morning grogginess
- Vivid dreams
- Headache

### Also known as

- Delta sleep-inducing peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [DSIP Side Effects: What Research Actually Reports](<https://pepflow.app/blog/dsip-side-effects/>)
- [DSIP dosage guide](<https://pepflow.app/peptides/dsip/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
